An update on maternal medication‐related embryopathies
- 10 June 2020
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 40 (9) , 1168-1177
Abstract
There is a general perception that any exposure to medication during pregnancy poses a potential risk to the fetus. Most available data about teratogenic drugs is derived from animal studies, case reports, or cohort studies. As a result, counseling women and their partners about the safety of drugs during pregnancy can be difficult due to limited information about efficacy, pharmacokinetics, and teratogenicity of some drugs. However, this should always be done in the context of weighing up potential teratogenic risks with the perinatal risks of an untreated medical or psychiatric condition. Ideally, this counseling should occur prior to a planned pregnancy so that medications and treatment of chronic medical conditions can be optimized. It is important that clinicians providing antenatal care are able to confidently manage women including utilizing appropriate resources. This paper aims at reviewing a selected (non‐exhaustive) list of the most commonly prescribed medications considered significant human teratogens and provides recommendations for pre‐conception and antenatal counseling.Keywords
This publication has 66 references indexed in Scilit:
- ISUOG Practice Guidelines: performance of first‐trimester fetal ultrasound scanUltrasound in Obstetrics & Gynecology, 2012
- The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor BlockersObstetrics and Gynecology International, 2011
- Teratogenic exposuresAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2011
- Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockersReproductive Toxicology, 2011
- Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic DrugsNew England Journal of Medicine, 2009
- Frances Kelsey & Thalidomide in the US: A Case Study Relating to Pharmaceutical RegulationsThe American Biology Teacher, 2002
- Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled studyReproductive Toxicology, 1999
- Fetal valproate syndrome.Journal of Medical Genetics, 1995
- “Proof” of human teratogenicityTeratology, 1994
- Retinoic Acid EmbryopathyNew England Journal of Medicine, 1985